MHC2-SCALE enhances identification of immunogenic neoantigens.

ABSTRACT: Recent studies suggest that CD4⁺ T cells can exert potent anti-tumor effects and improve immunotherapy efficacy by aiding CD8⁺ T cells. However, characterizing the mechanism of CD4⁺ T cells' anti-tumor activity has been challenging due to inaccurate major histocompatibility complex class II (MHC-II) peptide prediction algorithms and the lack of high-quality reagents for immune monitoring. To address this, we developed MHC2-substitution of CLIP and analytical LCMS evaluation (MHC2-SCALE), a streamlined approach combining affinity optimized class II-associated invariant chain peptide (CLIP) exchange technology, high throughput 2D-LCMS analysis, and rapid generation of peptide-bound MHC-II monomers for subsequent multimer assembly. We validated MHC-II peptide

SUBMITTER: Gober JG 

PROVIDER: S-EPMC11999303 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature